Hey-Hadavi, Juliana
Seekins, Daniel
Palmer, Melissa
Coffey, Denise
Caminis, John
Abdullaev, Sandzhar
Patwardhan, Meenal
Tyler, Haifa
Raheja, Ritu
Stanley, Ann Marie
Pineda-Salgado, Liliam
Bourdet, David L.
Andrade, Raul J.
Hayashi, Paul H.
Dimick-Santos, Lara
Rockey, Don C.
Estilo, Alvin
Article History
Accepted: 1 February 2021
First Online: 16 March 2021
Declarations
:
: No funding was received to assist with the preparation of this manuscript.
: Dr Dimick-Santos has no conflict of interest related to this paper. Dr Hey-Hadavi, Dr Seekins, Ms Coffey, Dr Caminis, Dr Abdullaev, Dr Patwardhan, Ms Tyler, Ms Raheja, Dr Pineda Salgado, Dr Bourdet, and Dr Estilo are full time employees of Pfizer, Bristol-Myers Squibb, Bristol-Myers Squibb, Sanofi, Bristol-Myers Squibb, AbbVie, Otsuka Pharmaceutical Development and Commercialization, Inc., AbbVie, Otsuka Pharmaceutical Development and Commercialization, Inc., Theravance Biopharma, and Otsuka Pharmaceutical Development and Commercialization, Inc, respectively. Dr Palmer was a full time employee of Takeda (formerly Shire) during the drafting of this paper and is now at Liver Consulting LLC. Dr Palmer serves as a consultant to several pharmaceutical companies for activities related to DILI, but has not derived any financial or other compensation from activities related to developing this document. Dr Stanley is an employee of Faegre Drinker Biddle and Reath LLP, which serves as Secretariat to the IQ Consortium, including the IQ DILI affiliate. Dr Andrade serves as a consultant to several pharmaceutical companies for activities related to NAFLD and DILI, but has not derived any financial or other compensation from activities related to developing this Best Practices document. Dr Hayashi declares that he has no relevant conflicts of interest for this paper. Dr Rockey declares that he has no relevant conflicts of interest for this paper. Dr Rockey has ongoing research grant support from Galectin Therapeutics, Genfit, Gilead Sciences, Intercept Pharmaceuticals, Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals and Sequana Medical, where his institution receives all funding.
: No ethics approvals were required for this manuscript.
: No consents were required.
: Data sharing is not applicable to this article as this is not a study.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
: All authors contributed to the manuscript in accordance with the guidance. All authors read and approved the final version.